Abstract
We developed a facile synthesis process for producing optically active non-secosteroidal ligands (YR301-304), which are stereoisomers of LG190178, and evaluated their performance in transcriptional assays using mutant vitamin D receptor (VDR). It was found that all of them had stronger activities than the natural ligand 1α,25-dihydroxyvitamin D3 [1α,25(OH)2D3]. In particular, YR301 showed potent activity for both wild-type and mutant Arg274Leu VDR.
Keywords: Asymmetric reduction, vitamin D receptor, mutant vitamin D receptor, non-secosteroidal ligand, transcriptional assay, molecular modeling study
Letters in Organic Chemistry
Title: Facile Synthesis of Stereoisomers of the Non-Secosteroidal Ligand LG190178 and their Evaluation Using the Mutant Vitamin D Receptor
Volume: 8 Issue: 1
Author(s): Yosuke Demizu, Aki Nakatsu, Yukiko Sato, Shinobu Honzawa, Atsushi Yamashita, Takayuki Sugiura, Atsushi Kittaka, Shigeaki Kato, Haruhiro Okuda and Masaaki Kurihara
Affiliation:
Keywords: Asymmetric reduction, vitamin D receptor, mutant vitamin D receptor, non-secosteroidal ligand, transcriptional assay, molecular modeling study
Abstract: We developed a facile synthesis process for producing optically active non-secosteroidal ligands (YR301-304), which are stereoisomers of LG190178, and evaluated their performance in transcriptional assays using mutant vitamin D receptor (VDR). It was found that all of them had stronger activities than the natural ligand 1α,25-dihydroxyvitamin D3 [1α,25(OH)2D3]. In particular, YR301 showed potent activity for both wild-type and mutant Arg274Leu VDR.
Export Options
About this article
Cite this article as:
Demizu Yosuke, Nakatsu Aki, Sato Yukiko, Honzawa Shinobu, Yamashita Atsushi, Sugiura Takayuki, Kittaka Atsushi, Kato Shigeaki, Okuda Haruhiro and Kurihara Masaaki, Facile Synthesis of Stereoisomers of the Non-Secosteroidal Ligand LG190178 and their Evaluation Using the Mutant Vitamin D Receptor, Letters in Organic Chemistry 2011; 8 (1) . https://dx.doi.org/10.2174/157017811794557804
DOI https://dx.doi.org/10.2174/157017811794557804 |
Print ISSN 1570-1786 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6255 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Advances in Nanomedicine Towards Clinical Application in Oncology and Immunology
Current Pharmaceutical Biotechnology Advances in Targeting Insulin-like Growth Factor Signaling Pathway in Cancer Treatment
Current Pharmaceutical Design Current Status and Perspectives Regarding the Treatment of Osteosarcoma: Chemotherapy
Reviews on Recent Clinical Trials MicroRNA and Bone Tumor: To Up Date
Current Signal Transduction Therapy Control of the Bone Morphogenetic Protein 7 Gene in Developmental and Adult Life
Current Genomics Is the Expression of Deoxynucleoside Kinases and 5'-nucleotidases in Animal Tissues Related to the Biological Effects of Nucleoside Analogs?
Current Medicinal Chemistry Notch-Associated MicroRNAs in Cancer
Current Drug Targets The “Big Five” Phytochemicals Targeting Cancer Stem Cells: Curcumin, EGCG, Sulforaphane, Resveratrol and Genistein
Current Medicinal Chemistry The Pathophysiological Role of PEDF in Bone Diseases
Current Molecular Medicine Estrogen(s) and Analogs as a Non-Immunogenic Endogenous Ligand in Targeted Drug/DNA Delivery
Current Medicinal Chemistry Could Growth Factor-Mediated Extracellular Matrix Deposition and Degradation Offer the Ground for Directed Pharmacological Targeting in Fibrosarcoma?
Current Medicinal Chemistry Anti-Insulin Receptor Antibodies in the Pathology and Therapy of Diabetes Mellitus
Current Diabetes Reviews NPY Signalling Pathway in Bone Homeostasis: Y1 Receptor as a Potential Drug Target
Current Drug Targets Gene Delivery for Periodontal Tissue Engineering: Current Knowledge – Future Possibilities
Current Gene Therapy Persistent GP130/STAT3 Signaling Contributes to the Resistance of Doxorubicin, Cisplatin, and MEK Inhibitor in Human Rhabdomyosarcoma Cells
Current Cancer Drug Targets Carbon Nanotubes for Biomaterials in Contact with Bone
Current Medicinal Chemistry MicroRNAs in Esophageal Adenocarcinoma: Functional Significance and Potential for the Development of New Molecular Disease Markers
Current Pharmaceutical Design Efficient Growth Inhibition of Human Osteosarcoma Cells Using a Peptide Derived from the MDM-2-Binding Site of p53
Protein & Peptide Letters Cucurbitacin B Induces DNA Damage, G2/M Phase Arrest, and Apoptosis Mediated by Reactive Oxygen Species (ROS) in Leukemia K562 Cells
Anti-Cancer Agents in Medicinal Chemistry Telomere Recombination and the ALT Pathway: A Therapeutic Perspective for Cancer
Current Pharmaceutical Design